ArticleNature communications2025

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Sidsel Pedersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.